MKV Stock Overview
Manufactures and supplies veterinary pharmaceutical products in Vietnam and Indochina. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cai Lay Veterinary Pharmaceutical Joint Stock Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₫9,100.00 |
52 Week High | ₫11,800.00 |
52 Week Low | ₫8,000.00 |
Beta | 0.59 |
1 Month Change | -1.09% |
3 Month Change | -3.19% |
1 Year Change | -4.21% |
3 Year Change | -37.24% |
5 Year Change | n/a |
Change since IPO | 9.48% |
Recent News & Updates
Recent updates
Shareholder Returns
MKV | VN Pharmaceuticals | VN Market | |
---|---|---|---|
7D | 1.1% | 2.8% | -0.04% |
1Y | -4.2% | 35.4% | 11.1% |
Return vs Industry: MKV underperformed the VN Pharmaceuticals industry which returned 35.4% over the past year.
Return vs Market: MKV underperformed the VN Market which returned 11.1% over the past year.
Price Volatility
MKV volatility | |
---|---|
MKV Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 3.6% |
Market Average Movement | 3.5% |
10% most volatile stocks in VN Market | 6.8% |
10% least volatile stocks in VN Market | 2.0% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine MKV's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | n/a | n/a | cailayvetco.com |
Cai Lay Veterinary Pharmaceutical Joint Stock Company manufactures and supplies veterinary pharmaceutical products in Vietnam and Indochina. The company offers veterinary medicine, aquatic medicine, and animal nutrition. It provides products for cattle, pig, chicken, duck, dog, cat, fish, and other species through distributors and agents.
Cai Lay Veterinary Pharmaceutical Joint Stock Company Fundamentals Summary
MKV fundamental statistics | |
---|---|
Market cap | ₫45.50b |
Earnings (TTM) | ₫6.89b |
Revenue (TTM) | ₫109.52b |
6.6x
P/E Ratio0.4x
P/S RatioIs MKV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MKV income statement (TTM) | |
---|---|
Revenue | ₫109.52b |
Cost of Revenue | ₫77.10b |
Gross Profit | ₫32.42b |
Other Expenses | ₫25.53b |
Earnings | ₫6.89b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 1.38k |
Gross Margin | 29.61% |
Net Profit Margin | 6.29% |
Debt/Equity Ratio | 0% |
How did MKV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 00:01 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/03/31 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cai Lay Veterinary Pharmaceutical Joint Stock Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|